Healthcare
Live Price
Offline$18.64
-6.61% today
1Y Change
-21.02%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sartorius Stedim Biotech S.A. (SRTOY) is a Healthcare stock with a market cap of $15.25B and listed on OTC. The stock last traded around $18.64 and down 21.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +2.5%, EPS growth of -85.6%, a dividend yield of 0.4%. What stands out right now is revenue +2.5%, EPS -85.6%, free cash flow -70.6% with operating margin 18.5% and ROIC 5.5%. The dividend is present but secondary, with a yield around 0.4%. Valuation already assumes a fairly strong business story at P/E 56.9 and price/sales 5.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SRTOY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SRTOY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SRTOY Max Drawdown
-32.25%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SRTOY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.9B
-17.3% YoY
FY Net Income
$414.4M
-52.7% YoY
Free Cash Flow
$372.0M
+104.7% YoY
Revenue Growth
+2.5%
EPS Growth
-85.6%
Gross Margin
44.7%
Net Margin
9.0%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.9B | 2.8B | 2.8B | 3.5B | 2.9B |
| Gross Profit | 1.3B | 1.2B | 1.2B | 1.8B | 1.6B |
| Operating Income | 527M | 371M | 485M | 1.1B | 683M |
| EBITDA | 833M | 671M | 756M | 1.3B | 812M |
| Net Income | 255M | 175M | 310M | 876M | 414M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 426M | 679M | 117M | 107M | 224M |
| Total Assets | 8.0B | 8.3B | 7.7B | 5.1B | 4.0B |
| Total Liabilities | 3.9B | 4.2B | 5.1B | 2.6B | 2.2B |
| Shareholder Equity | 4.1B | 4.0B | 2.6B | 2.4B | 1.7B |
| Total Debt | 2.7B | 2.9B | 3.7B | 1.1B | 626M |
| Net Debt | 2.3B | 2.2B | 3.6B | 1.0B | 402M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
696M
+13.7% YoY
Capital Expenditures
324M
+24.8% YoY
Free Cash Flow
372M
+104.7% YoY
Key ratios
Gross Margin
44.7%
Operating Margin
18.5%
Net Margin
9.0%
ROE
6.6%
Debt / Equity
0.64x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.